Physician profile
Laurie E Boyd
NPI 1356328124
$1,896.38
in general payments reported to CMS, 2019-2025
15 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $693 · 2022: $525 · 2023: $166 · 2024: $411 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $670 · Education: $8.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $669.96 |
| Education | $8.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $483.03 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $313.40 | 2021-2024 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Abbvie INC. | $301.74 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $258.17 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $101.99 | 2024-2025 | Cobenfy |
| Glaxosmithkline, LLC. | $79.07 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $76.80 | 2021 | |
| Corium, LLC | $44.74 | 2023 | Azstarys |
| Amarin Pharma, INC. | $44.47 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $42.47 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $39.29 | 2021 | |
| Amgen INC. | $38.67 | 2021-2022 | |
| Lundbeck LLC | $34.50 | 2022-2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $19.52 | 2022 | |
| Supernus Pharmaceuticals, INC. | $18.52 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurie Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.